Prelude Therapeutics to Participate in Citizens Life Sciences Conference
Prelude Therapeutics (NASDAQ: PRLD), un'azienda di oncologia di precisione in fase clinica, ha annunciato la sua partecipazione alla prossima Citizens Life Sciences Conference a New York il 7 maggio 2025. Il team dirigenziale dell'azienda, composto dal CEO Kris Vaddi, dalla Presidente e CMO Jane Huang e dalla CSO Peggy Scherle, parteciperà a una conversazione informale alle 11:00 ET.
Prelude Therapeutics si dedica allo sviluppo di farmaci innovativi per pazienti oncologici, con un portafoglio che include degradatori SMARCA2 di prima classe (sia endovenosi che orali) e un inibitore di CDK9. L'azienda sta inoltre avanzando nello sviluppo di Precision ADCs attraverso partnership strategiche.
Prelude Therapeutics (NASDAQ: PRLD), una compañía de oncología de precisión en etapa clínica, anunció su participación en la próxima Citizens Life Sciences Conference en Nueva York el 7 de mayo de 2025. El equipo directivo de la empresa, incluyendo al CEO Kris Vaddi, la Presidenta y CMO Jane Huang, y la CSO Peggy Scherle, participará en una charla informal a las 11:00 a.m. ET.
Prelude Therapeutics se especializa en desarrollar medicamentos innovadores para pacientes con cáncer, con una cartera que incluye degradadores SMARCA2 de primera clase (tanto intravenosos como orales) y un inhibidor de CDK9. La compañía también está avanzando en ADCs de precisión mediante asociaciones.
Prelude Therapeutics (NASDAQ: PRLD)는 임상 단계의 정밀 종양학 회사로, 2025년 5월 7일 뉴욕에서 열리는 Citizens Life Sciences Conference에 참여한다고 발표했습니다. CEO Kris Vaddi, 사장 겸 CMO Jane Huang, CSO Peggy Scherle 등 회사 경영진이 오전 11시(동부시간)에 파이어사이드 채팅에 참여할 예정입니다.
Prelude Therapeutics는 암 환자를 위한 혁신적인 의약품 개발에 주력하고 있으며, 파이프라인에는 일류 SMARCA2 분해제(정맥주사 및 경구용)와 CDK9 억제제가 포함되어 있습니다. 또한 파트너십을 통해 정밀 ADC 개발도 진행 중입니다.
Prelude Therapeutics (NASDAQ : PRLD), une société d'oncologie de précision en phase clinique, a annoncé sa participation à la prochaine Citizens Life Sciences Conference à New York le 7 mai 2025. L'équipe dirigeante de l'entreprise, comprenant le CEO Kris Vaddi, la présidente et CMO Jane Huang, ainsi que la CSO Peggy Scherle, participera à une discussion informelle à 11h00 ET.
Prelude Therapeutics se spécialise dans le développement de médicaments innovants pour les patients atteints de cancer, avec un portefeuille comprenant des dégradeurs SMARCA2 de première classe (intraveineux et oraux) ainsi qu'un inhibiteur de CDK9. La société fait également progresser les ADCs de précision via des partenariats.
Prelude Therapeutics (NASDAQ: PRLD), ein klinisch fortgeschrittenes Präzisions-Onkologie-Unternehmen, gab seine Teilnahme an der bevorstehenden Citizens Life Sciences Conference in New York am 7. Mai 2025 bekannt. Das Führungsteam des Unternehmens, darunter CEO Kris Vaddi, Präsidentin und CMO Jane Huang sowie CSO Peggy Scherle, wird um 11:00 Uhr ET an einem Fireside-Chat teilnehmen.
Prelude Therapeutics spezialisiert sich auf die Entwicklung innovativer Medikamente für Krebspatienten, mit einer Pipeline, die erstklassige SMARCA2-Degrader (sowohl IV als auch oral) und einen CDK9-Inhibitor umfasst. Das Unternehmen treibt zudem Precision ADCs durch Partnerschaften voran.
- None.
- None.
WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference taking place in New York on May 7, 2025.
On Wednesday, May 7, 2025, at 11:00 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Jane Huang, M.D., President and Chief Medical Officer, and Peggy Scherle, Ph.D., Chief Scientific Officer will participate in a fireside chat.
A live webcast of the fireside chat can be accessed on the Company’s website under Events and Presentations. The recording will be archived and available on the Company’s website for 90 days.
About Prelude Therapeutics
Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com.
Investor Contact:
Robert Doody
Senior Vice President, Investor Relations
Prelude Therapeutics
484.639.7235
RDoody@preludetx.com
FAQ
When is Prelude Therapeutics (PRLD) presenting at the Citizens Life Sciences Conference?
Who will be presenting at the PRLD fireside chat during the Citizens Life Sciences Conference?
What are the main drug candidates in Prelude Therapeutics' pipeline?
Where can investors access the webcast of Prelude Therapeutics' presentation?
